勃林格殷格翰宣布,BioNTech公司将负责供应实验性药物Pumitamig,并作为Ib/II期临床研究的监管申办方。这项合作标志着双方在肿瘤治疗领域迈出关键一步。
该研究将评估Pumitamig在特定患者群体中的安全性与有效性。通过整合资源与专业能力,两家企业旨在加速创新疗法的开发进程。
勃林格殷格翰宣布,BioNTech公司将负责供应实验性药物Pumitamig,并作为Ib/II期临床研究的监管申办方。这项合作标志着双方在肿瘤治疗领域迈出关键一步。
该研究将评估Pumitamig在特定患者群体中的安全性与有效性。通过整合资源与专业能力,两家企业旨在加速创新疗法的开发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.